Scholarlink

<p>Androgen deprivation therapy (ADT) for prostate cancer is carried out in a&#xa0;palliative approach in symptomatic geriatric patients. Testosterone synthesis is suppressed using a&#xa0;dual therapy principle with luteinising hormone-releasing hormone (LH-RH) analogues or antagonists of LH-RH, in addition to modern antiandrogens. Additional administration of taxanes is initially possible in cases of high tumor burden and aggressive tumor biology, which is otherwise reserved for castration-resistant prostate cancer. The ADT is a&#xa0;systemic therapy for all testosterone-dependent processes and can lead to hot flushes, gynecomastia, osteoporosis, sarcopenia, anemia, falls, cognitive decline, depression, metabolic syndrome, increased cardiovascular events and many drug interactions. In patients identified as geriatric, ADT should therefore only be used after a&#xa0;thorough risk-benefit analysis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Androgendeprivative Therapie des Prostatakarzinoms aus geriatrischer Sicht

  • 期刊论文

  • 发表日期：

    2025年6月23日

查看全文
  • A. Wiedemann,
  • K. Becher,
  • A. Manseck,
  • J. Stein,
  • M. Fröhner,
  • C. Fiebig,
  • A. Piotrowski,
  • R. Kirschner-Hermanns,
  • A. Bannowsky,
  • S. Wirz,
  • J. Salem,
  • T. H. Kuru

摘要

Androgen deprivation therapy (ADT) for prostate cancer is carried out in a palliative approach in symptomatic geriatric patients. Testosterone synthesis is suppressed using a dual therapy principle with luteinising hormone-releasing hormone (LH-RH) analogues or antagonists of LH-RH, in addition to modern antiandrogens. Additional administration of taxanes is initially possible in cases of high tumor burden and aggressive tumor biology, which is otherwise reserved for castration-resistant prostate cancer. The ADT is a systemic therapy for all testosterone-dependent processes and can lead to hot flushes, gynecomastia, osteoporosis, sarcopenia, anemia, falls, cognitive decline, depression, metabolic syndrome, increased cardiovascular events and many drug interactions. In patients identified as geriatric, ADT should therefore only be used after a thorough risk-benefit analysis.